English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background : The immune status is usually hampered in patients of diabetes mellitus. The global pandemic of diabetes principally involves type 2 diabetes. In diabetic patients higher prevalence of hepatitis B virus infection is also noted that leads to more severe complications. This study was conducted to determine the immune responses to hepatitis B vaccine in type 2 diabetic patients. Methods : In this study 33 diabetic patients were included as experimental group and 34 non diabetic healthy persons were included as control group. All the participants were vaccinated with hepatitis B vaccine following 0, 1, 6 months schedule. The vaccine responses in diabetic and non diabetic group were compared depending on seromarkers (anti-HBs titer, IL-2 and IFN-?) following vaccination. Results : The mean value of anti-HBs titer was lower in diabetic group (357.81 mIU/ml) than non diabetic group (621.24 mIU/ml) but the difference was not significant (p>0.05), the mean value of IFN-? was lower in diabetic group (0.1480 IU/ml) than non diabetic group (0.2788 IU/ml) and here the difference was significant (p 0.05). Conclusion : The study revealed no statistically significant variation in anti-HBs and IL-2 but a diminished IFN-? level as the immune response in diabetic patients after HBV infection. J MEDICINE January 2016; 17 (1) : 8-11

IL-2, IFN-?³ and anti-HBs based Immune Responses to Hepatitis B Vaccine in Type 2 Diabetic Patients